tazobactam has been researched along with ertapenem in 20 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (ertapenem) | Trials (ertapenem) | Recent Studies (post-2010) (ertapenem) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 850 | 89 | 485 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castanheira, M; Samuelsen, Ø; Spencer, J; Walsh, TR | 1 |
| Girlich, D; Nordmann, P; Poirel, L | 1 |
| Bonomo, RA; Distler, AM; Endimiani, A; Hornick, JM; Hujer, AM; Hujer, KM; Papp-Wallace, KM; Taracila, M | 1 |
| Abendroth, J; Atkins, K; Boyer, SH; Clifton, MC; Dudley, MN; Durso, S; Griffith, DC; Hecker, SJ; Hirst, GC; King, P; Lomovskaya, O; Loutit, JS; Morgan, EE; Potts, KT; Raymond, A; Reddy, KR; Sabet, M; Sun, D; Tarazi, Z; Totrov, M; Tsivkovski, R | 1 |
| Ceesay, TP; Gesser, R; Graham, DR; Holtom, P; Lucasti, C; Malafaia, O; McAdams, A; Nichols, RL; Perez, NQ; Woods, GL | 1 |
| Citron, DM; Gesser, RM; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, Y | 1 |
| Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 1 |
| Zaĭtsev, AA | 1 |
| Adeyi, B; Angel-Muller, E; Hague, C; Higareda, I; Ismail, M; Roy, S; Teppler, H; Woods, GL | 1 |
| Gesser, RM; McCarroll, KA; Woods, GL | 1 |
| Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM | 1 |
| An, MM; Chen, ML; Jiang, YY; Liu, P; Shen, H; Wang, R; Zhang, JD; Zou, Z | 1 |
| Amancio Martins, W; Bahia, JL; Cara, DC; Coutinho, SC; DE Macedo Farias, L; Galuppo Diniz, C; Lopes DE Andrade, JP; Morais Apolonio, AC; Nicoli, JR; Roque DE Carvalho, MA; Valéria Dos Santos, K | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
| Dizbay, M; Karaşahin, EF; Karaşahin, Ö; Özger, HS | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
| Hsueh, PR; Jean, SS; Ko, WC; Lee, YL; Liu, PY; Lu, MC | 1 |
| Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K | 1 |
1 review(s) available for tazobactam and ertapenem
| Article | Year |
|---|---|
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2009 |
7 trial(s) available for tazobactam and ertapenem
| Article | Year |
|---|---|
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Lactams; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Skin Diseases; Staphylococcus aureus; Tazobactam; Treatment Outcome | 2002 |
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Double-Blind Method; Enzyme Inhibitors; Ertapenem; Humans; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Skin Diseases, Bacterial; Tazobactam | 2002 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
[Carbapenem antibiotic ertapenem in the treatment of extrahospital intraabdominal infections].
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2003 |
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ertapenem; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lactams; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Tazobactam; Treatment Outcome | 2003 |
Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Infusions, Intravenous; Lactams; Logistic Models; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Skin Diseases; Statistics, Nonparametric; Tazobactam; Treatment Outcome | 2004 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
12 other study(ies) available for tazobactam and ertapenem
| Article | Year |
|---|---|
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
Topics: Acremonium; Bacterial Proteins; beta-Lactamases; Catalysis; Catalytic Domain; Cefepime; Ceftazidime; Cephalosporins; Kinetics; Models, Molecular; Mutation; Penicillinase; Protein Structure, Tertiary; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2008 |
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blotting, Southern; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; France; Fresh Water; Gram-Negative Bacteria; Health Surveys; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas fluorescens; Water Microbiology | 2010 |
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporinase; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulbactam; Tazobactam | 2010 |
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Boronic Acids; Carbapenems; Crystallography, X-Ray; Drug Resistance, Bacterial; Drug Synergism; Gram-Negative Bacteria; Heterocyclic Compounds, 1-Ring; Mice; Microbial Sensitivity Tests; Models, Molecular; Rats; Stereoisomerism; Structure-Activity Relationship | 2015 |
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Escherichia coli; Escherichia coli Infections; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2004 |
In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; beta-Lactam Resistance; beta-Lactams; Ertapenem; Germ-Free Life; In Vitro Techniques; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Tazobactam; Virulence | 2010 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Superinfection; Tazobactam; Treatment Outcome | 2016 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Taiwan; Tazobactam | 2022 |
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam | 2023 |